JACC. Case reports · 2026
ApoC-III Antisense Oligonucleotide Therapy Used in Glycogen Storage Disease Type 1a.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Burns Joseph, Sutton V Reid, Zachariah Justin P
Аннотация
BACKGROUND: Glycogen storage disease type 1a (GSD1a) is an autosomal recessive disorder characterized by impaired glycogenolysis and gluconeogenesis. Individuals with GSD1a manifest significant hypertriglyceridemia refractory to dietary and lipid-lowering medication therapies. Apolipoprotein C-III antisense oligonucleotide (apoCIII-ASO) therapy is approved to reduce severe hypertriglyceridemia in familial chylomicronemia syndrome but is also effective in moderate hypertriglyceridemia of varied genetic backgrounds.
EARLY REPORTS SUMMARY: We describe a 22-year-old with GSD1a and hypertriglyceridemia with past pancreatitis despite fibric acid derivative, niacin, and bempedoic acid therapy in whom apoCIII-ASO was associated with triglyceride reduction from 4,951 to 1,643 mg/dL.
DISCUSSION: As GSD1a-associated hypertriglyceridemia is often refractory to standard therapies, apoCIII-ASO therapy may offer promise as a treatment.
NOVELTY: This case describes the first use of apoCIII-ASO in GSD1a-related hypertriglyceridemia.
TAKE-HOME MESSAGE: GSD1a-driven hypertriglyceridemia may be treatable using apoCIII-ASO.
EARLY REPORTS SUMMARY: We describe a 22-year-old with GSD1a and hypertriglyceridemia with past pancreatitis despite fibric acid derivative, niacin, and bempedoic acid therapy in whom apoCIII-ASO was associated with triglyceride reduction from 4,951 to 1,643 mg/dL.
DISCUSSION: As GSD1a-associated hypertriglyceridemia is often refractory to standard therapies, apoCIII-ASO therapy may offer promise as a treatment.
NOVELTY: This case describes the first use of apoCIII-ASO in GSD1a-related hypertriglyceridemia.
TAKE-HOME MESSAGE: GSD1a-driven hypertriglyceridemia may be treatable using apoCIII-ASO.